Skip directly to search Skip directly to A to Z list Skip directly to site content
CDC Home

Volume 10, Number 5—May 2004

Research

Clinical Manifestations, Laboratory Findings, and Treatment Outcomes of SARS Patients

Jann-Tay Wang*, Wang-Huei Sheng*, Chi-Tai Fang*, Yee-Chun Chen*, Jiun-Ling Wang*, Chong-Jen Yu*, Shan-Chwen Chang*Comments to Author , and Pan-Chyr Yang*
Author affiliations: *National Taiwan University Hospital, Taipei, Taiwan

Main Article

Table 3

Data on most severe abnormal laboratory parameters of 76 SARS patients during their disease coursea

Laboratory parameters
(no. of patients, %) Mean ± SD of most severe data (unit) Duration from disease onset to most severe data noted
Leukopenia (40, 52.6)
2.5 ± 0.7 (x 109/L)
7.5 ± 2.4 days
Lymphopenia (72, 94.7)
0.6 ± 0.3 (X 109/L)
7.0 ± 2.5 days
Thrombocytopenia (61, 80.3)
102.3 ± 31.3 (X 109/L)
6.9 ± 2.0 days
Elevated AST (66, 86.9)
142.0 ± 323.6 (U/L)
10.3 ± 4.6 days
Elevated ALT (59, 77.6)
103.7 ± 132.2 (U/L)
13.3 ± 5.0 days
Elevated LDH (73, 96.1)
1323.8 ± 1487.2 (U/L)
10.8 ± 3.9 days
Elevated CK (34, 44.7)
12165.7 ± 58226.9 (U/L)
7.8 ± 4.2 days
Elevated CRP (71, 93.4) 7.1 ± 4.0 (mg/dL) 8.5 ± 3.0 days

aSARS, severe acute respiratory syndrome; SD, standard deviation.

Main Article

Top of Page

USA.gov: The U.S. Government's Official Web PortalDepartment of Health and Human Services
Centers for Disease Control and Prevention   1600 Clifton Rd. Atlanta, GA 30333, USA
800-CDC-INFO (800-232-4636) TTY: (888) 232-6348 - Contact CDC–INFO